You are here: Home » Reuters » News
Business Standard

Novartis goes after Roche asthma medicine Xolair with new drug

Reuters  |  ZURICH 

(Reuters) - said it is pushing ahead with a late-stage study of its experimental drug after announcing the outperformed Roche's Xolair in a Phase II against urticaria, also known as

The move sets the stage for a new head-to-head battle between the Swiss drug giants. Xolair had 1.74 billion Swiss francs ($1.75 billion) in sales in 2017 and is a pillar of Roche's immunology franchise, but sees an opportunity and plans two Phase III studies with more than 2,000 patients who suffer from chronic spontaneous (CSU).

($1 = 0.9960 Swiss francs)

(Reporting by John Miller; editing by Thomas Seythal)

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

First Published: Tue, December 04 2018. 12:32 IST